Articles

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Axitinib injectable suspension phase 1/2a trial enrolls first patients

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Amydis announces successful pre-IND meeting with FDA to develop retinal tracer for amyloid angiopathy diagnosis

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.

Saving the world: Pharmaceutical innovation in nine months

Evolving Clinical Practice: Insights Gained from Real-World Evidence

Navigating Real-World Evidence in Ophthalmology

Conducting An Audit and Using Real-World Evidence in Your Practice

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.



What an intravitreal integrin antagonist may bring to DME

Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.

Post hoc analysis: Protocol V provides more practical DME guidance for clinicians

Videos

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease. 

Safety and efficacy of KPI-121 0.25% for DED treatment

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Analyzing an investigational ophthalmic solution for treating presbyopia-related symptoms

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 

Evaluating long-term safety of micro-bypass implant + phaco in PXG

Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

Violet light-filtering IOLs: visual and non-visual benefits

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Drug delivery vs drops: Controlling postop pain, inflammation in cataract patients

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Single administration of intracameral bimatoprost implant: IOP lowering, safety

Analyses of IRIS Registry data capture a snapshot of patient visits and receipt of anti-VEGF injections.

Pandemic’s impact on US ophthalmology patient care: Real-world insights

Prospective randomized trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

What a proposed biosimilar may mean for subfoveal wet AMD 

A study including data from about 42,000 eyes found diabetic retinopathy (DR) severity is a risk factor for the progression of diabetic eye disease. Other findings support the idea that genetic factors influence the development of proliferative DR versus diabetic macular edema. 



Research suggests course of diabetic eye disease influenced by genetic factors

Study highlights the role of demographic and socioeconomic characteristics as contributors to disease- and treatment-related disparities among patients with diabetic macular edema.

Identifying gaps in anti-VEGF treatment among minorities with DME

Podcasts

Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.

Integrating AI to manage DR in a primary care setting

A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.